Target intelligence / Profile preview

E3 ubiquitin-protein ligase TRIM63 (TRIM63)

Target
TRIM63
Molecular classification
Enzyme, E3 ubiquitin ligase, RING zinc finger protein, Tripartite motif (TRIM) family protein
01

Overview

E3 ubiquitin-protein ligase TRIM63 (commonly called MuRF1) is an enzyme predominantly expressed in striated muscle and is a key regulator of muscle protein catabolism[1][2][3]. It belongs to the RING-type E3 ubiquitin ligase subgroup within the tripartite motif (TRIM) protein family, distinguished by their zinc finger domains and coiled-coil regions that mediate protein-protein interactions[3]. TRIM63 is localized at the sarcomere Z-line and M-line where it interacts with proteins such as titin and myosin[1][2][3]. Its primary function is tagging specific muscle proteins, especially myosin, for proteasomal degradation—a process upregulated during periods of muscle atrophy, disuse, glucocorticoid treatment, or cachexia[1][2][4]. Genetically, variants in TRIM63 are associated with certain forms of hypertrophic cardiomyopathy[1]. As a central mediator of muscle protein breakdown, TRIM63 is a validated target for skeletal muscle wasting and related conditions, although no drugs are yet approved to target it directly. Upregulation of TRIM63/MuRF1 is routinely used as a molecular biomarker for muscle atrophy[1].

Other names
MuRF1Muscle RING Finger 1RING finger protein 28Tripartite motif-containing protein 63Muscle-specific RING finger protein 1MURF1RNF28SMRZIris ring finger proteinStriated muscle RING zinc finger proteinCMH31
02

Mechanism of action

Induction of ubiquitination and degradation of muscle proteins (e.g., myosin heavy chain, creatine kinase, actin) Regulation of sarcomere stability and muscle cell structure

03

Biological functions

Protein ubiquitinationProteasome-mediated protein degradationRegulation of muscle protein turnoverMuscle remodelingInhibition of muscle protein synthesis during starvation
04

Disease associations

Muscle atrophyHypertrophic cardiomyopathyMetabolic diseaseCachexia (muscle wasting in disease states)
05

Safety considerations

Targeting TRIM63 could risk exacerbating muscle loss or affecting cardiac function; broad inhibition of E3 ligases may disrupt protein homeostasis and cause toxicity or unwanted effects on muscle mass[6]
06

Interacting drugs

No clinically approved drugs directly target TRIM63 (as of now); experimental modulating compounds or proteasome inhibitors may indirectly influence its pathway[6]
07

Biomarkers

Upregulation of TRIM63 (MuRF1) mRNA is used as a biomarker of active skeletal muscle atrophy[1]

Beyond the preview

Go deeper on E3 ubiquitin-protein ligase TRIM63 (TRIM63).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on E3 ubiquitin-protein ligase TRIM63 (TRIM63).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call